Evidence map›Paper›PMID 26366426›Full record

ArticleMolecular therapy. Methods & clinical development2015

Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice.

Shuo You, Mallappa Anitha, Sean Md deSouza, Dingwu Jia, Xianghua Lu, Miroslaw Kozlowski, Darin E Olson, Shanthi Srinivasan, Peter M Thulé

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Regenerative medicine and cell-based approaches to restore pancreatic function.Nature reviews. Gastroenterology & hepatology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shuo YouDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA ; Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya Hospital, Central South University , Changsha, China ; Key Laboratory of Diabetes Immunology, National Clinical Research Center for Metabolic Diseases, Ministry of Education , Changsha, China.
Mallappa AnithaDepartment of Internal Medicine, Division of Digestive Diseases, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Sean Md deSouzaDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Dingwu JiaDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Xianghua LuDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Miroslaw KozlowskiDepartment of Pathology and Laboratory Medicine, Translational Research Program, Center for Cellular Immunotherapy, University of Pennsylvania , Philadelphia, Pennsylvania, USA.
Darin E OlsonDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Shanthi SrinivasanDepartment of Internal Medicine, Division of Digestive Diseases, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Peter M ThuléDepartment of Internal Medicine, Division of Endocrinology, Metabolism & Lipids, Atlanta VA Medical Center, Emory University, School of Medicine , Atlanta, Georgia, USA.
Atlanta VA Medical Center · USEmory University · USUniversity of Pennsylvania · US

Funding

Mechanism of Enteric NeuropathyR01DK080684 · NIDDK · EMORY UNIVERSITY · PI Shanthi K Srinivasan · 2009 to 2026
$6.1M
NIDDK NIH HHS R01 DK080684
6 · The paper itself

Abstract

Depending on the population examined, from 6 to 83% of people with diabetes mellitus exhibit symptoms of altered gut motility, manifesting as dysphagia, reflux, early satiety, nausea, abdominal pain, diarrhea, or constipation. Hyperglycemia-induced cell loss within the enteric nervous system has been demonstrated in both diabetic rodents and patients with diabetes. Glycemic control is recommended to prevent diabetic gastroenteropathy but is often difficult to achieve with current treatment modalities. We asked if hepatic insulin gene therapy (HIGT) could inhibit the development of diabetic gastroenteropathy in mice. Bowel length, bowel transit, colonic muscle relaxation, and the numbers of both stimulatory and inhibitory neurons in the colonic myenteric plexus were compared in groups of diabetic mice (DM), control nondiabetic mice (Con), and diabetic mice treated with HIGT (HIGT). Delivery of a metabolically responsive insulin transgene to the liver of STZ-diabetic mice with an adeno-associated virus, sero-type 8 (AAV8) produced near-normal blood sugars for over 1 month and prevented anatomic, functional, and neurohistologic changes observed in diabetic mice. We conclude that in addition to normalizing oxidative metabolism in diabetic rodents, HIGT is sufficient to prevent the development of diabetic gastroenteropathy.

Identifiers

PMID26366426
PMCPMC4557470
OpenAlexW2356798092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.